JP2013512268A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013512268A5 JP2013512268A5 JP2012541422A JP2012541422A JP2013512268A5 JP 2013512268 A5 JP2013512268 A5 JP 2013512268A5 JP 2012541422 A JP2012541422 A JP 2012541422A JP 2012541422 A JP2012541422 A JP 2012541422A JP 2013512268 A5 JP2013512268 A5 JP 2013512268A5
- Authority
- JP
- Japan
- Prior art keywords
- mitotic checkpoint
- compounds
- schmidt
- present
- inhibition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000017205 mitotic cell cycle checkpoint Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 150000008523 triazolopyridines Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09075534.9 | 2009-11-30 | ||
| EP09075534A EP2343295A1 (en) | 2009-11-30 | 2009-11-30 | Triazolopyridine derivates |
| PCT/EP2010/068298 WO2011064328A1 (en) | 2009-11-30 | 2010-11-26 | Triazolopyridine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013512268A JP2013512268A (ja) | 2013-04-11 |
| JP2013512268A5 true JP2013512268A5 (enExample) | 2014-01-09 |
| JP5805654B2 JP5805654B2 (ja) | 2015-11-04 |
Family
ID=42027882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012541422A Expired - Fee Related JP5805654B2 (ja) | 2009-11-30 | 2010-11-26 | トリアゾロピリジン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20130121994A1 (enExample) |
| EP (2) | EP2343295A1 (enExample) |
| JP (1) | JP5805654B2 (enExample) |
| CN (1) | CN102753547B (enExample) |
| CA (1) | CA2782012A1 (enExample) |
| ES (1) | ES2532655T3 (enExample) |
| WO (1) | WO2011064328A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2343297A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| UY33452A (es) * | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| ES2544609T3 (es) | 2010-12-17 | 2015-09-02 | Bayer Intellectual Property Gmbh | Imidazopirazinas 2-sustituidas para uso como inhibidores de Mps-1 y TTK en el tratamiento de trastornos hiper-proliferativos |
| WO2012080228A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Pharma Aktiengesellschaft | 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| CA2821819A1 (en) | 2010-12-17 | 2012-06-21 | Marcus Koppitz | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| EP2651944B1 (en) | 2010-12-17 | 2015-09-23 | Bayer Intellectual Property GmbH | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| CA2821829A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| CN103429591A (zh) | 2010-12-17 | 2013-12-04 | 拜耳知识产权有限责任公司 | 在治疗过度增殖性病症中用作mps-1和tkk抑制剂的6-取代的咪唑并吡嗪 |
| JP6001049B2 (ja) | 2011-03-31 | 2016-10-05 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | Ｍｐｓ−１キナーゼ阻害剤としての置換ベンズイミダゾール類 |
| CA2832310A1 (en) | 2011-04-06 | 2012-10-11 | Bayer Intellectual Property Gmbh | Substituted imidazopyridines and intermediates thereof |
| WO2012160029A1 (en) | 2011-05-23 | 2012-11-29 | Bayer Intellectual Property Gmbh | Substituted triazolopyridines |
| UA112096C2 (uk) * | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
| JP6166289B2 (ja) | 2012-03-14 | 2017-07-19 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換イミダゾピリダジン |
| BR112015000308A2 (pt) | 2012-07-10 | 2017-06-27 | Bayer Pharma AG | método para preparo de triazolopiridinas substituídas |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| CN103965199B (zh) * | 2013-02-02 | 2017-07-07 | 广东东阳光药业有限公司 | 一种芳杂环化合物、包含它的药物组合物及其用途 |
| AR096469A1 (es) * | 2013-06-06 | 2015-12-30 | Bayer Pharma AG | Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas |
| EP3007692A1 (en) * | 2013-06-11 | 2016-04-20 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor |
| PE20160156A1 (es) | 2013-06-11 | 2016-04-20 | Bayer Pharma AG | Derivados de prodroga de triazolpiridinas sustituidas |
| EP2860177A3 (en) | 2013-09-20 | 2015-06-10 | Bayer Intellectual Property GmbH | Synthesis of functionalized arenes |
| EP3283642B1 (en) | 2015-04-17 | 2023-10-11 | Netherlands Translational Research Center Holding B.V. | Prognostic biomarkers for ttk inhibitor chemotherapy |
| GB201522532D0 (en) * | 2015-12-21 | 2016-02-03 | Cancer Rec Tech Ltd | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives |
| CN107641118B (zh) * | 2016-07-22 | 2020-11-06 | 爱科诺生物医药股份有限公司 | 具有细胞坏死抑制活性的化合物及其组合物和应用 |
| NZ780966A (en) | 2019-04-18 | 2026-02-27 | Univ Johns Hopkins | Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof |
| IL301817A (en) | 2020-10-13 | 2023-06-01 | Univ Johns Hopkins | Modified 4-([4,2,1]triazolo[5,1-a]pyridin-6-yl)thiophene-2-carboxamide histories and their use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| RU2007109778A (ru) | 2004-08-17 | 2008-09-27 | Галдерма Ресерч Энд Девелопмент, С.Н.С. (Fr) | Новые биароматические соединения, которые активируют рецепторы типа ppar, и их применение в косметических и фармацевтических композициях |
| ES2549862T3 (es) * | 2006-08-30 | 2015-11-02 | Cellzome Limited | Derivados de triazol como inhibidores de quinasa |
| EP2178868A1 (en) * | 2007-07-18 | 2010-04-28 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
| MX2010002115A (es) * | 2007-08-23 | 2010-06-01 | Aztrazeneca Ab | 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos. |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP2222674B8 (en) * | 2007-11-27 | 2016-01-06 | Cellzome Limited | Amino triazoles as pi3k inhibitors |
| WO2010092015A1 (en) * | 2009-02-10 | 2010-08-19 | Cellzome Limited | Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors |
| CN102317288A (zh) * | 2009-02-13 | 2012-01-11 | 佛维雅制药公司 | 作为激酶抑制剂的[1,2,4]三唑并[1,5-a]吡啶 |
-
2009
- 2009-11-30 EP EP09075534A patent/EP2343295A1/en not_active Withdrawn
-
2010
- 2010-11-26 CA CA2782012A patent/CA2782012A1/en not_active Abandoned
- 2010-11-26 CN CN201080061523.7A patent/CN102753547B/zh not_active Expired - Fee Related
- 2010-11-26 JP JP2012541422A patent/JP5805654B2/ja not_active Expired - Fee Related
- 2010-11-26 US US13/512,721 patent/US20130121994A1/en not_active Abandoned
- 2010-11-26 WO PCT/EP2010/068298 patent/WO2011064328A1/en not_active Ceased
- 2010-11-26 EP EP10787724.3A patent/EP2507236B1/en not_active Not-in-force
- 2010-11-26 ES ES10787724.3T patent/ES2532655T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013512263A5 (enExample) | ||
| JP2013503824A5 (enExample) | ||
| JP2013512264A5 (enExample) | ||
| Duan et al. | EZH2: a novel target for cancer treatment | |
| Kepp et al. | ATP and cancer immunosurveillance | |
| Liu et al. | Targeting CDK12 for cancer therapy: function, mechanism, and drug discovery | |
| Do et al. | Wee1 kinase as a target for cancer therapy | |
| JP2022050493A (ja) | 癌を治療する方法における使用のための毛細血管拡張性運動失調症の変異したＲａｄ３関連タンパク質キナーゼ（ＡＴＲ）の阻害剤 | |
| Jhaveri et al. | HSP90 inhibitors for cancer therapy and overcoming drug resistance | |
| TW202045181A (zh) | 細胞週期蛋白依賴性激酶2生物標記物及其用途 | |
| EP4048270A1 (en) | Pharmaceutical combination of prmt5 inhibitors | |
| JP2016533366A5 (enExample) | ||
| EP4335511A3 (en) | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy | |
| JP2018510193A (ja) | Ｌｓｄ１阻害剤としてのヘテロ環式化合物 | |
| JP6060163B2 (ja) | キナーゼインヒビターとしてのベンゾニトリル誘導体 | |
| KR20180130575A (ko) | 정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합 | |
| AU2018212647A1 (en) | Combination therapy involving diaryl macrocyclic compounds | |
| JP2017500338A5 (enExample) | ||
| JP2015512943A5 (enExample) | ||
| JP2009507918A5 (enExample) | ||
| TW200808802A (en) | Imidazopyrazines as protein kinase inhibitors | |
| BR112014027337A2 (pt) | composições orgânicas para tratar doenças relacionadas com kras | |
| MX2014000635A (es) | Derivados de piridin-2(1h)-ona como inhibidores de jak. | |
| WO2019015561A1 (en) | TREATMENT OF CANCERS USING A COMBINATION COMPRISING INHIBITORS OF PARP, TEMOZOLOMIDE AND / OR RADIOTHERAPY | |
| JP2014532751A5 (enExample) |